Identification of PEG10 and TSG101 as Carcinogenesis, Progression, and Poor-Prognosis Related Biomarkers for Gallbladder Adenocarcinoma Research First Online: 01 April 2011 Received: 13 November 2010 Accepted: 16 March 2011 DOI :
10.1007/s12253-011-9394-7
Cite this article as: Liu, D., Yang, Z. & Jiang, S. Pathol. Oncol. Res. (2011) 17: 859. doi:10.1007/s12253-011-9394-7
14
Citations
237
Downloads
Abstract PEG10 is a transcriptional factor while TSG101 is involved in numerous cellular processes, including apoptotic resistance. Overexpression of PEG10 and TSG101 were observed in a variety of human cancers. However, their expression and clinical significance in gallbladder cancer (GBC) have not yet been identified. To understand the tumor biology of GBC at the molecular level, we examined PEG10 and TSG101 expression in 108 adenocarcinomas, 15 gallbladder polyps, 35 chronic cholecystitis tissues, and 46 peritumoral tissues by using immunohistochemistry. Overexpression of PEG10 and TSG101 was detected in gallbladder adenocarcinoma (48.1% and 47.2%, respectively). Conversely, there was less expression detected in the peritumoral tissues (19.6%), adenomatous polyps (13.3%), and gallbladder epithelium with chronic cholecystitis (5.1%) (p < 0.01, p < 0.05, and p < 0.01, respectively). Notably, the benign lesions with positive PEG10 and/or TSG101 expression showed moderately or severely atypical hyperplasia in gallbladder epithelium. The overexpression of PEG10 and TSG101 was significantly associated with differentiation, tumor mass, lymph node metastasis and invasion of adenocarcinoma. Univariate Kaplan-Meier analysis showed that overexpression of PEG10 (p = 0.041) and TSG101 (p = 0.025) was closely associated with decreased overall survival. Multivariate Cox regression analysis revealed that positive expression of PEG10 (p = 0.036) or TSG101 (p = 0.022) is a predictor of poor prognosis in gallbladder adenocarcinoma. Our study suggested that overexpression of PEG10 and TSG101 might be closely related to the carcinogenesis, progression, clinical biological behaviors, and prognosis of gallbladder adenocarcinoma.
Keywords Gallbladder cancer Gallbladder polyp Chronic cholecystitis PEG10 TSG101
References 1.
Ono R, Kobayashi S, Wagatsuma H et al (2001) A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics 73:232–237
PubMed CrossRef Google Scholar 2.
Okabe H, Satoh S, Furukawa Y et al (2003) Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 63:3043–3048
PubMed Google Scholar 3.
Kainz B, Shehata M, Bilban M et al (2007) Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer 121:1984–1993
PubMed CrossRef Google Scholar 4.
Tsuji K, Yasui K, Gen Y et al (2010) PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet 198:118–125
PubMed CrossRef Google Scholar 5.
Chunsong H, Yuling H, Li W et al (2006) CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23 + CD5+ B cells. J Immunol 177:6713–6722
PubMed Google Scholar 6.
Li CM, Margolin AA, Salas M et al (2006) PEG10 is a c-MYC target gene in cancer cells. Cancer Res 66:665–672
PubMed CrossRef Google Scholar 7.
Ip WK, Lai PB, Wong NL et al (2007) Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett 250:284–91
PubMed CrossRef Google Scholar 8.
Jie X, Lang C, Jian Q et al (2007) Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene 26:5741–5751
PubMed CrossRef Google Scholar 9.
Lux A, Beil C, Majety M et al (2005) Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1. J Biol Chem 280:8482–8493
PubMed CrossRef Google Scholar 10.
Ono R, Nakamura K, Inoue K et al (2006) Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality. Nat Genet 38:101–106
PubMed CrossRef Google Scholar 11.
Liu RT, Huang CC, You HL et al (2002) Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21:4830–4837
PubMed CrossRef Google Scholar 12.
Young TW, Rosen DG, Mei FC et al (2007) Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin Cancer Res 13:3848–3854
PubMed CrossRef Google Scholar 13.
Koon N, Schneider-Stock R, Sarlomo-Rikala M et al (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53:235–240
PubMed CrossRef Google Scholar 14.
Ma XR, Edmund Sim UH, Pauline B et al (2008) Overexpression of WNT2 and TSG101 genes in colorectal carcinoma. Trop Biomed 25:46–57
PubMed Google Scholar 15.
Li L, Liao J, Ruland J et al (2001) A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc Natl Acad Sci USA 98:1619–1624
PubMed CrossRef Google Scholar 16.
Li L, Cohen SN (1996) Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85:319–329
PubMed CrossRef Google Scholar 17.
Zhu G, Gilchrist R, Borley N et al (2004) Reduction of TSG101 protein has a negative impact on tumor cell growth. Int J Cancer 109:541–547
PubMed CrossRef Google Scholar 18.
Bashirova AA, Bleiber G, Qi Y et al (2006) Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J Virol 80:6757–6763
PubMed CrossRef Google Scholar 19.
Goldin RD, Roa JC (2009) Gallbladder cancer: a morphological and molecular update. Histopathology 55:218–229
PubMed CrossRef Google Scholar 20.
Gatto M, Bragazzi MC, Semeraro R et al (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42:253–260
PubMed CrossRef Google Scholar 21.
Jayaraman S, Jarnagin WR (2010) Management of gallbladder cancer. Gastroenterol Clin North Am 39:331–342
PubMed CrossRef Google Scholar 22.
Maurya SK, Tewari M, Mishra RR (2010) Genetic abberations in gallbladder cancer. Surg Oncol Sep 28. [Epub ahead of print]
23.
Sanada Y, Yoshida K, Ohara M, Tsutani Y (2007) Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res 13:105–113
PubMed CrossRef Google Scholar 24.
Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH (2007) Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13:326–335
PubMed CrossRef Google Scholar 25.
Németh Z, Szász AM, Somorácz A, Tátrai P, Németh J et al (2009) Zonula Occludens-1, Occludin, and E-cadherin Protein Expression in Biliary Tract cancers. Pathol Oncol Res 15:533–539
PubMed CrossRef Google Scholar 26.
Li Q, Yang Z (2009) Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp& Clin Cancer Res 28:65–72
CrossRef Google Scholar 27.
Li Q, Yang Z, Liu J, et al (2010). Expression of CDx2 and Hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic typr and clinical outcome. Pathol Oncol Res Dec 28. 2010 [Epub ahead of print]
28.
Malik IA (2004) Gallbladder cancer: current status. Expert Opin Pharmacother 5:1271–1277
PubMed CrossRef Google Scholar 29.
Tucek S, Tomasek J, Halámkova J (2010) Bile duct malignancies. Klin Onkol 23:231–241
PubMed Google Scholar 30.
Zhao Y, You H, Liu F et al (2002) Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett 185:211–218
PubMed CrossRef Google Scholar 31.
Shen H, Pan Y, Han Z et al (2004) Reversal of multidrug resistance of gastric cancer cells by downregulation of TSG101 with TSG101siRNA. Cancer Biol Ther 3:561–565
PubMed Google Scholar 32.
Lee CT, Park KH, Yanagisawa K et al (2004) Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res 64:6660–6665
PubMed CrossRef Google Scholar 33.
Lee CT, Lee YJ, Kwon SY et al (2006) In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27. Cancer Res 66:372–377
PubMed CrossRef Google Scholar 34.
Huang Q, Zhang X, Wang H et al (2004) A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 10:1439–1445
PubMed CrossRef Google Scholar © Arányi Lajos Foundation 2011
Authors and Affiliations 1. Department of Geriatric Surgery Central South University Hunan China 2. Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital Central South University Hunan China